Pregabalin Capsule
Product Images NDC 63629-8197

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 63629-8197). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl636298197)

Pregabalin Capsules, USP 100 mg label from Bryant Ranch Prepack. The label includes the NDC 63629-8197-01, a barcode, and indicates the package contains 30 capsules. Storage instructions and a caution to keep out of reach of children are also present.*

FDA Label Image

Label (Lbl6362981972)

Label for Pregabalin 100 mg capsules from Bryant Ranch Prepack. The label indicates the product is an orange capsule, compares to Lyrica 100 mg capsules by ScieGen Pharmaceuticals Inc, and is packaged in a quantity of 30. It includes storage instructions (20°-25°C), a lot number, an NDC code 63629-8197, and warnings to keep out of reach of children.*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. Four lines indicate treatment groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph compares the efficacy of different Pregabalin dosages in pain improvement.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline, showing two treatments: Pregabalin 100 mg three times a day and placebo. The y-axis represents the percent of patients improved, and the x-axis shows the percent improvement in pain from baseline. The graph features two lines, demonstrating greater patient improvement with Pregabalin compared to placebo across the range of pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg taken twice daily, compared to placebo. The graph shows curves representing patient improvement percentages across varying pain improvement thresholds.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph depicting the percent of patients improved against percent improvement in pain from baseline, comparing Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The graph shows the efficacy of different Pregabalin doses compared to placebo over various pain improvement thresholds.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing percent improvement in pain from baseline against the percent of patients improved. The graph shows three curves labeled for Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating patient improvement distributions across pain reduction percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart comparing responder rates (%) across different dosages of Pregabalin and placebo in two studies, Study E1 and Study E3. Study E1 shows increasing responder rates from placebo to 600 mg/day under BID (twice daily) dosing. Study E3 compares placebo to 300 mg/day and 600 mg/day dosed BID and TID (three times daily). Statistically significant results versus placebo are indicated.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline plotted against dose (mg/day) for different studies labeled E1, E2, and E3 with dosing regimens BD and TID. The graph includes data points with significant p-values indicating statistical results for seizure reduction at various doses compared to placebo.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 800 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, showing how patient improvement varies across these doses.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart comparing the estimated percentage of subjects without LTR (likely loss to response) over 180 days between Pregabalin and placebo. The y-axis represents the estimated percentage of subjects without LTR, and the x-axis indicates days. The Pregabalin group is shown with a solid line, while the placebo group is depicted with a dashed line, illustrating higher estimated survival without LTR in the Pregabalin group throughout the period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved from baseline to week 12 using BOCF method. The x-axis shows percent improvement ranging from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100. Two lines represent Pregabalin and Placebo, with Pregabalin consistently showing higher percentages of improvement across the improvement range.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph depicting the percent of subjects improved versus the percent improved from baseline to week 16 based on BOCF. Two lines compare Pregabalin and placebo, with the Pregabalin group showing a higher percentage of improvement across the range compared to placebo.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A text panel displaying the formula for creatinine clearance (CLcr) calculation. The formula involves age in years, weight in kilograms, serum creatinine concentration in mg/dL, and a correction factor of 0.85 for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, depicting its molecular formula with an amino group (NH2), a carboxyl group (CO2H), and an isobutyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.